Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide

J Pediatr. 2002 Dec;141(6):830-2. doi: 10.1067/mpd.2002.129849.

Abstract

We report the use of inhaled prostacyclin (PGI(2)) in 4 neonates with persistent pulmonary hypertension and hypoxemia refractory to inhaled nitric oxide. Oxygenation rapidly improved after inhalation of PGI(2) in all infants. The condition of one infant subsequently deteriorated, and alveolar capillary dysplasia was found at autopsy. The surviving infants were discharged with normal oxygen saturations in room air.

MeSH terms

  • Administration, Inhalation
  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / therapeutic use
  • Epoprostenol / administration & dosage*
  • Epoprostenol / therapeutic use
  • Humans
  • Infant, Newborn
  • Nitric Oxide / administration & dosage*
  • Nitric Oxide / therapeutic use
  • Persistent Fetal Circulation Syndrome / drug therapy*
  • Vasodilator Agents / administration & dosage*
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Vasodilator Agents
  • Nitric Oxide
  • Epoprostenol